Background: Maintenance and repeated pulmonary rehabilitation programs (PRPs) for patients with COPD have attempted to prolong PRP benefits beyond 12-24 months. However, there is limited evidence as to the magnitude of benefit or the ideal interval between repeating the program under "real-world" conditions in which patients are referred based on clinical necessity. Therefore, we reviewed the effects of repeating PRP in a physician-referred cohort of patients with COPD.
Methods: A total of 141 individuals with COPD completed PRP twice and 35 completed PRP three times over a 12-year period. We used linear mixed-effects models to quantify the magnitude and change in 6-minute walk distance (6MWD), St George's Respiratory Questionnaire (SGRQ), and Hospital Anxiety and Depression Scale (HADS) for each PRP. One-way analysis of variance with Tukey's post hoc analysis compared the effects of different time intervals on 6MWD, SGRQ, and HADS between PRPs.
Results: Despite 39 mL/year average decrease in forced expiratory volume in 1 second, overall 6MWD improved following each PRP (PRP1=58 m, <0.0001; PRP2=42 m, <0.0001; PRP3=32 m, <0.003). Mean SGRQ decreased after PRP1 (-7.0 units; <0.001) and PRP2 (-4.9 units; <0.0001) but not after PRP3 (-3.2 units; =0.10). HADS decreased after PRP1 (-1.9 units; <0.0001) and PRP2 (-1.7 units; =0.0001) but not after PRP3 (-0.4 units; =0.63).
Conclusion: In physician-referred patients who underwent repeat PRP as clinically required, there were clear benefits in functional exercise capacity following each repeat PRP, which was not affected by the time interval between PRPs. Health-related quality of life and mood improved after the first two PRPs, but not after a third.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388229 | PMC |
http://dx.doi.org/10.2147/COPD.S131778 | DOI Listing |
Introduction: Those with established symptomatic cardiopulmonary disease should attend secondary prevention programs. Attendance at these programs is known to differ by sex and by smoking status, with females and those who smoke being less likely to attend. However, little is known about whether the risk factors of being female and smoking are cumulative, and how outcomes from secondary prevention differ by these subgroups.
View Article and Find Full Text PDFPediatr Pulmonol
January 2025
Department of Pediatric Chest Diseases, Faculty of Medicine, Gazi University, Ankara, Turkey.
Background And Objectives: Patients with primary ciliary dyskinesia (PCD) have a reduction in exercise capacity from the early stages. Although there are studies investigating these patients' lower extremity exercise capacity using various methodologies, there needs to be more research on the functional exercise capacity of the upper extremities. This study aimed to compare pulmonary function, upper extremity functional exercise capacity, muscle oxygenation, muscle strength, and physical activity level in children with PCD and controls.
View Article and Find Full Text PDFMonaldi Arch Chest Dis
January 2025
Postgraduate Program in Medical Sciences, State University of Rio de Janeiro; Piquet Carneiro Polyclinic, State University of Rio de Janeiro; Rehabilitation Sciences Postgraduate Program, Augusto Motta University Centre, Rio de Janeiro.
With the increasing use of highly effective modulator therapy (HEMT) in adults with cystic fibrosis (awCF), it is necessary to determine the evolution of the most dynamic physiological markers of this disease, such as the 6-minute walk test (6MWT) and the Glittre-activities of daily living test (TGlittre). The present study aimed to evaluate the 1-year changes in the 6- minute walking distance (6MWD), TGlittre time, and quality of life (QoL) in awCF before the initiation of HEMT and to determine the impact of habitual physical activity (HPA) and chest physiotherapy (CP). This longitudinal study enrolled 24 awCF who completed the 6MWT and TGlittre.
View Article and Find Full Text PDFJ Asthma
January 2025
Division of Pneumology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, AOU Sant'Andrea, 00189 Rome, Italy.
Objective: It remains unclear whether baseline FENO levels can predict response to anti-IL5/5R biologic treatment in patients with severe asthma.
Methods: We recruited 104 patients with severe eosinophilic asthma treated with anti-IL5/anti-IL5R for at least one year who had measured FeNO values before the beginning of anti-eosinophilic treatment. Population was divided into subjects with FeNO < 25 and ≥25 ppb.
Respir Res
January 2025
School of Engineering, University of Warwick, Coventry, CV4 7AL, UK.
Introduction And Objectives: High flow nasal cannula (HFNC) therapy is an increasingly popular mode of non-invasive respiratory support for the treatment of patients with acute hypoxemic respiratory failure (AHRF). Previous experimental studies in healthy subjects have established that HFNC generates flow-dependent positive airway pressures, but no data is available on the levels of mean airway pressure (mP) or positive end-expiratory pressure (PEEP) generated by HFNC therapy in AHRF patients. We aimed to estimate the airway pressures generated by HFNC at different flow rates in patients with AHRF, whose functional lung volume may be significantly reduced compared to healthy subjects due to alveolar consolidation and/or collapse.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!